Health and Healthcare
Huge Biotech Index Rebalance Means Massive Buy Orders for 5 Stocks
Published:
On the close Friday, the NYSE Arca Biotechnology Index is set for a rebalance. What this means is the index will be rebalanced to reflect reweighting allocations across the stocks that make up the index. It also means there will be some serious buying and selling on the last print.
In a research note, the analysts at Cowen have calculated the buys and sells in the index based on the holdings in the First Trust Biotechnology ETF, which essentially mirrors the index and will rebalance as well. The Cowen analysts estimate there are seven stocks rebalancing with greater than 30% of 10-day average volume. We screened the list for the five stocks that could see the highest amount of share count buying and had the highest percentage of volume increase over the 10-day average.
Grifols S.A. (NASDAQ: GRFS) will see a huge order on the close. The Cowen team expects 569,400 shares of the stock to be purchased. That will represent a gigantic 203% increase over the 10-day average volume of the stock. Grifols is a specialty biopharmaceutical company, develops, manufactures and distributes plasma derivative products in the United States, Canada, the European Union and elsewhere. The stock closed most recently at $32.50.
ALSO READ: 3 Top Big Pharmaceutical Stocks With Upcoming Catalysts
PDL Biopharma Inc. (NASDAQ: PDLI) will see a gigantic buy order hit the tap on the close. The Cowen team estimates that 3,057,000 shares of the stock will be bought. That represents a 113% increase in the 10-day average selling volume. The company manages a portfolio of patents and royalty assets in the United States and Europe. The stock closed Thursday at $6.56.
Myriad Genetics Inc. (NASDAQ: MYGN) will see a pretty solid buy on the close. The analysts expect 302,300 shares of the stock will be purchased. That represents a 44% increase in the 10-day average volume. Myriad Genetics is a molecular diagnostic company that focuses on the development and marketing of predictive, personalized and prognostic medicine tests in the United States and internationally. The stock closed Thursday at $34.97.
Nektar Therapeutics Inc. (NASDAQ: NKTR) will see a large block hit the buy tape on the close. The analysts are expecting 449,500 shares of the stock to be purchased Friday. That represents a 37% increase in the 10-day average volume. This biopharmaceutical company develops drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the United States. The stock closed on Thursday at $12.62.
Charles River Laboratories International Inc. (NYSE: CRL) will see a sizable buy on the close. The Cowen staff figures that 186,100 shares of the stock will be bought on the last print. That will be a 29% increase in the 10-day average volume. This early-stage contract research company provides drug discovery and preclinical development services worldwide. The stock closed Thursday at $75.12.
ALSO READ: Merrill Lynch’s 5 High-Dividend Growth Stocks to Buy Now
While it is no secret that these purchases will be made, it certainly will put a floor under these stocks. It also gives sellers a chance to have market-on-close sell or buy orders in to match up with all the trading.
A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.
Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.